Navigation Links
Nano-sized technology has super-sized effect on tumors
Date:4/2/2008

Anyone facing chemotherapy would welcome an advance promising to dramatically reduce their dose of these often harsh drugs. Using nanotechnology, researchers at Washington University School of Medicine in St. Louis have taken a step closer to that goal.

The researchers focused a powerful drug directly on tumors in rabbits using drug-coated nanoparticles. They found that a drug dose 1,000 times lower than used previously for this purpose markedly slowed tumor growth.

"Many chemotherapeutic drugs have unwanted side effects, and we've shown that our nanoparticle technology has the potential to increase drug effectiveness and decrease drug dose to alleviate harmful side effects," says lead author Patrick M. Winter, Ph.D., research assistant professor of medicine and biomedical engineering.

The nanoparticles are extremely tiny beads of an inert, oily compound that can be coated with a wide variety of active substances. In an article published online in The FASEB Journal, the researchers describe a significant reduction of tumor growth in rabbits that were treated with nanoparticles coated with a fungal toxin called fumagillin. Human clinical trials have shown that fumagillin can be an effective cancer treatment in combination with other anticancer drugs.

In addition to fumagillin, the nanoparticles' surfaces held molecules designed to stick to proteins found primarily on the cells of growing blood vessels. So the nanoparticles latched on to sites of blood vessel proliferation and released their fumagillin load into blood vessel cells. Fumagillin blocks multiplication of blood vessel cells, so it inhibited tumors from expanding their blood supply and slowed their growth.

Human trials have also shown that fumagillin can have neurotoxic side effects at the high doses required when given by standard methods. But the fumagillin nanoparticles were effective in very low doses because they concentrate where tumors create new blood vessels. The rabbits that received fumagillin nanoparticles showed no adverse side effects.

Senior author Gregory M. Lanza, M.D., Ph.D., associate professor of medicine and of biomedical engineering, and Samuel A. Wickline, M.D., professor of medicine, of physics and of biomedical engineering, are co-inventors of the nanoparticle technology. The nanoparticles measure only about 200 nanometers across, or 500 times smaller than the width of a human hair. Their cores are composed mostly of perfluorocarbon, a safe compound used in artificial blood.

The nanoparticles can be adapted to many different medical applications. In addition to carrying drugs to targeted locations, they can be manufactured to highlight specific targets in magnetic resonance imaging (MRI), nuclear imaging, CT scanning and ultrasound imaging.

In this study, researchers loaded blood-vessel-targeted nanoparticles with MRI contrast agent and were able to make detailed maps of tumor blood vessel growth using standard MRI equipment. The MRI scans showed that blood vessel formation tended to concentrate in limited areas on the surface at one side of tumors instead of dispersing uniformly, which was a surprise.

"Using the blood-vessel targeted nanoparticles, we get a far more complete view of tumor biology than we would get with any other technique," Winter says. "If you followed a tumor over a period of time with the nanoparticles and MRI scans, you would have a much better understanding of the tumor's reaction to treatment."

The researchers say they believe nanoparticle technology will be very useful for monitoring cancer treatment results in both the short and long term.

"It gives you a way of determining whether you should continue treatment, change the dose or even try a different treatment altogether," Lanza says.

Prior work has shown that the nanoparticles can be loaded with many kinds of drugs. The researchers used fumagillin nanoparticles in these experiments to demonstrate the feasibility of this approach, but they plan further investigations with other versions of the nanoparticles.

"What this report clearly demonstrates is that our nanoparticles can carry chemotherapeutic drugs specifically to tumors and have an effect at the tumor site," Lanza says. "Sometimes when I give presentations about our nanotechnology, people react as if it was science fiction or at best a technology of the distant future. But we've shown that the technology is ready for medical applications now."

The nanoparticles will be tested this year in preliminary human clinical trials to determine the optimal method for using them as imaging agents. These studies will lay essential groundwork for using the nanoparticles as therapeutic agents.


'/>"/>

Contact: Gwen Ericson
ericsong@wustl.edu
314-286-0141
Washington University School of Medicine
Source:Eurekalert  

Related medicine news :

1. Nano-sized voltmeter measures electric fields deep within cells
2. Digital Technology Exposes Business to Greater Liability
3. Technology Shines at 2008 NJTC Venture Conference; Best in Show Winners Announced
4. Older People Want to Use Technology to Help Them Remain at Home
5. Blue Cross Blue Shield of Arizona Renews EDS Information Technology Services Contract
6. Rigel to Present at 8th Annual Fortis Bank Biotechnology Conference
7. FluoroPharma Inc. Expands Technology Platform to Include Agents for Alzheimers Disease (AD)
8. New Technology Improves the Appearance of Cellulite in a Single Treatment
9. Visiprise Named One of the Top Manufacturing Technology Providers
10. Danny Calegari Appointed the Richard Merkin Distinguished Professor of Mathematics at the California Institute of Technology
11. Ochsner Health System Partners with DocuSys for Presurgical Care, AIMS and Medication Management Technology
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Nano-sized technology has super-sized effect on tumors
(Date:12/4/2016)... Newport Beach, CA (PRWEB) , ... December 04, ... ... youthful appearance without undergoing major cosmetic surgery can now take advantage of a ... is an advanced skin rejuvenation treatment that reduces the appearance of age spots, ...
(Date:12/4/2016)... ... December 04, 2016 , ... Responsible dental care hinges on regular ... to achieve optimal results. This important necessity inspired an inventor from Las Vegas, Nev., ... to ensure that people break or avoid bad techniques of brushing the teeth in ...
(Date:12/2/2016)... ... December 02, 2016 , ... Lori G. Cohen and ... office, will speak at the American Conference Institute’s 21st Drug & Medical Device ... a Lead Sponsor of the conference. , Cohen, who chairs the firm’s Pharmaceutical, Medical ...
(Date:12/2/2016)... Calif. (PRWEB) , ... December 02, 2016 , ... On ... at the Hard Rock Hotel San Diego honoring the 2016 MPN Heroes—eight individuals who ... neoplasms (MPNs) by going above and beyond the standard of care, demonstrating leadership within ...
(Date:12/2/2016)... ... December 02, 2016 , ... ... Area in Alabama are expected to attend the UNCF Dothan-Wiregrass Mayor’s Luncheon Dec. ... scholarship funds for area students and operating support to UNCF-member institutions, including Miles ...
Breaking Medicine News(10 mins):
(Date:12/2/2016)... , December 2, 2016 Orthopedic ... & Support) is Expected to Gain a Significant Market Share ... Orthopedic Ailments  ... , According to a ... on Medical Implants Sterile Packaging: Clamshell Product Type Segment Projected ...
(Date:12/2/2016)... N.J. , Dec. 2, 2016   CytoSorbents ... immunotherapy leader commercializing its European Union approved CytoSorb ... and cardiac surgery patients worldwide, announced that Dr. ... the 9th Annual LD Micro Main Event ... , 2016 at the Luxe Sunset Boulevard Hotel in ...
(Date:12/2/2016)... , December 2, 2016 On Thursday, ... 1.36%; the Dow Jones Industrial Average edged 0.36% higher, to ... down 0.35%. Losses were broad based as six out of ... initiated research reports on the following Services equities: Myriad Genetics ... QGEN ), INC Research Holdings Inc. (NASDAQ: ...
Breaking Medicine Technology: